Abstracts Archive - Page 725 of 2607 - ACR Meeting Abstracts

Abstract Number: 1946 • ACR Convergence 2021
Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial
Silje Watterdal Syversen¹, Guro Goll¹, Kristin Jørgensen², Marthe Brun¹, Øystein Sandanger³, Kristin Hammersbøen², Joseph Sexton¹, Inge Olsen³, Johanna Gehin⁴, David Warren³, Rolf Anton Klaasen³, Trude Bruun⁵, Maud Kristine Ljoså⁶, Anne Haugen⁷, Rune Njålla⁸, Brigitte Michelsen⁹, Camilla Zettel¹⁰, Yngvill Bragenes¹¹, Svanaug Skorpe¹², Eldri Strand¹³, Pawel Mielnik¹⁴, Cato Mørk¹⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad¹⁶ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Lillehammer, Nepal, ⁵The University Hospital of North Norway, Tromsø, Norway, ⁶Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, ⁷Østfold Hospital Trust, Moss, Norway, ⁸Nordland Hospital Trust, Bodø, Bodø, Norway, ⁹Hospital of Southern Norway Trust, Kristiansand, Norway, ¹⁰Betanien Hospital, Skien, Norway, ¹¹Vestre Viken Hospital Trust, Drammen, Norway, ¹²Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ¹³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹⁴Førde Hospital Trust, Førde, Norway, ¹⁵Akershus Dermatology Center, Lørenskog, Norway, ¹⁶Oslo University Hospital, Radiumhospitalet, Oslo, Norway
Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
Abstract Number: 1944 • ACR Convergence 2021
Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
Josef Smolen¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Stefan Siebert¹⁰, Elke Theander¹¹ and Laure Gossec¹², ¹Medical University of Vienna, Vienna, Austria, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹Janssen Cilag, Lund, Sweden, ¹²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: 1935 • ACR Convergence 2021
Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome
Teressa Shaw¹, Wei Zhang², Sara McCoy³, Xueer Qiu¹, Adam Pagenkopf¹, Robert Hal Scofield⁴, Jacques Galipeau³ and Yun Liang¹, ¹University of Wisconsin-Madison, Madison, WI, ²University of California San Diego, La Jolla, CA, ³University of Wisconsin, Madison, WI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Many autoimmune diseases feature increased prevalence in females, with primary Sjögren's syndrome (pSS) being the most female-predominant autoimmune disease with a female-to-male ratio of…
Abstract Number: PP06 • ACR Convergence 2021
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
Michael Linn¹ and Dan Smith², ¹Relapsing Polychondritis Foundation, New York, NY, ²Relapsing Polychondritis Foundation, Canton, MI
Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
Abstract Number: PP05 • ACR Convergence 2021
Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information
Michael Linn¹, Spenser Mestel² and Susie Ratledge³, ¹Relapsing Polychondritis Foundation, New York, NY, ²New York, NY, ³Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN
Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
Abstract Number: PP01 • ACR Convergence 2021
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
Dana Guglielmo, San Diego, CA
Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
Abstract Number: PP08 • ACR Convergence 2021
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
Aberdeen Allen, Colgate Palmolive, Parlin, NJ
Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
Abstract Number: PP12 • ACR Convergence 2021
Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
Guadalupe Torres¹, Courtney Wells² and Kristine Carandang³, ¹, ²University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, ³Global Healthy Living Foundation, CreakyJoints, San Diego, CA
Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Wigna Cruz, Puerto Rico
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
Abstract Number: PP04 • ACR Convergence 2021
Dual Roles: Thriving with SLE as a Medical Student
Chieh Lo¹ and Song-Chou Hsieh², ¹School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), ²Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
Abstract Number: 1938 • ACR Convergence 2021
A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions
Anurag Verma¹, Noah Tsao¹, Lauren Thomann², Yuk-Lam Ho², Rotonya Carr¹, Dana crawford³, Jimmy efird⁴, Jennifer Huffman², Adriana Hung⁵, Kerry Ivey², Sudha Iyengar³, Michael Levin⁶, Shiuh-Wen luoh⁷, Julie Lynch⁸, Pradeep Natarajan⁹, Saiju Pyarajan¹⁰, alexander Bick¹¹, Lauren Costa², Giulio Genovese¹², Richard Hauger¹³, Ravi madduri¹⁴, Gita Pathak¹⁵, Renato polimanti¹⁵, Benjamin Voight¹, Marijana Vujkovic¹, Maryam Zekavat¹⁵, Hongyu Zhao¹⁵, Marylyn Ritchie¹, Kyong-Mi Chang¹⁶, Kelly Cho², Juan casas², Phil Tsao¹⁷, J. Michael Gaziano², Christopher ODonnell², Scott Damrauer¹ and Katherine Liao¹⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Boston Healthcare System, Boston, MA, ³Case Western Reserve University, Cleveland, OH, ⁴DVAHCS, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Pennsylvania, Philadelphia, ⁷Oregon Health & Science University, Portland, ⁸VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Partners, Boston, ¹¹Vanderbilt University, Nashville, TN, ¹²Harvard Medical School, Boston, MA, ¹³University of California San Diego, San Diego, CA, ¹⁴Argon National Lab, Chicago, IL, ¹⁵Yale University, New Haven, CT, ¹⁶VA Philadelphia, Philadelphia, PA, ¹⁷VA Palo Alto, Palo Alto, CA, ¹⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Severe coronavirus disease 2019 (COVID-19) is associated with a broad range of clinical conditions. International efforts have led to the identification of risk alleles…
Abstract Number: 1911 • ACR Convergence 2021
Patient’s and Rheumatologist’s Perspectives on the Burden of Adverse Drug Reactions Attributed to Biologics: A Qualitative Study
Henrike Westerink¹, Leanne Kosse², Naomi Jessurun², Astrid van Tubergen³, Harald Vonkeman⁴, Mike Nurmohamed⁵, Bart van den Bemt⁶ and Marieke de Vries⁷, ¹Netherlands Pharmacovigilance Centre Lareb, Nijmegen, Netherlands, ²Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands, ³Maastricht UMC+, Maastricht, Netherlands, ⁴Medisch Spectrum Twente; University of Twente, Enschede, Netherlands, ⁵Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁶Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁷Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Previous studies showed a discrepancy between patient’s and HealthCare Professional (HCP) perspective on the burden of Adverse Drug Reactions (ADRs), where HCPs often underestimate…
Abstract Number: 1865 • ACR Convergence 2021
Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study
Umar Ghaffar¹, Kenneth Warrington², Stephanie Duong¹, Cynthia Crowson³, Michelle Burke¹, Boyd Viers¹, Aaron Potretzke¹, Haraldur Bjarnason¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, ³Mayo Clinic, Eyota, MN
Background/Purpose: Chronic periaortitis is an inflammatory condition that typically involves the infrarenal portion of the abdominal aorta. To date, no epidemiologic studies have been performed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].